What is Immunetics?
Immunetics operates within the dynamic biomedical and life sciences industry, providing a comprehensive suite of products and services. Their portfolio includes critical components such as antibodies, advanced diagnostic tests, gene editing tools, and diverse assay technologies. These offerings are tailored to meet the rigorous demands of clients in immunology, molecular biology, and veterinary diagnostics. The company's commitment to delivering high-quality reagents and kits supports both cutting-edge research and essential clinical applications. Through an established global distribution network, Immunetics effectively serves a broad spectrum of academic institutions and commercial laboratories worldwide, solidifying its role as a key player in scientific advancement.
How much funding has Immunetics raised?
Immunetics has raised a total of $8.1M across 5 funding rounds:
Grant
$2.4M
Grant
$500K
Unspecified
$629K
Grant
$3.7M
Debt
$835K
Grant (2011): $2.4M with participation from National Institutes of Health
Grant (2011): $500K led by The Massachusetts Life Sciences Center
Unspecified (2012): $629K, investors not publicly disclosed
Grant (2012): $3.7M featuring National Institutes of Health
Debt (2014): $835K, investors not publicly disclosed
Key Investors in Immunetics
National Institutes of Health
The National Institutes of Health (NIH) is the primary agency of the U.S. government responsible for biomedical and health-related research, supporting advancements in medicine and public health.
The Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is dedicated to fostering innovation and economic growth within the life sciences sector through strategic investments and support for research and commercialization.
What's next for Immunetics?
The recent major strategic investment positions Immunetics for significant advancement. This capital infusion, part of its $8.1M in total financing, suggests a phase of scaling operations, enhancing research and development capabilities, and potentially expanding its market reach. The company's focus on specialized biomedical products and diagnostic tools indicates a strategic direction towards addressing critical needs in immunology and molecular biology. Future endeavors will likely involve leveraging this backing to accelerate product innovation, strengthen its global presence, and forge new partnerships within the scientific community, further cementing its enterprise-level standing.
See full Immunetics company page
